Yahoo · Oct 12, 2026
Orthofix pays former executives $24M in damages
The payments were made after a California arbitrator found private text messages between Orthofix executives couldn’t be considered cause for firing.
NASDAQ · OFIX
Healthcare · Medical - Devices
$9.81
Down-$0.10 (-1.01%)
Updated Oct 26, 2026, 5:11 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OFIX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
OFIX closed at $9.81 after 20 trading sessions, down 0.30% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $9.92 | $9.99 | $9.67 | $9.81 | 247.6K |
| Oct 22, 2026 | $9.79 | $10.0583 | $9.79 | $9.99 | 336.77K |
| Oct 21, 2026 | $9.71 | $9.94 | $9.64 | $9.74 | 604.96K |
| Oct 20, 2026 | $9.68 | $9.95 | $9.68 | $9.85 | 335.29K |
| Oct 19, 2026 | $9.34 | $9.665 | $9.2848 | $9.59 | 296.09K |
| Oct 16, 2026 | $9.64 | $9.81 | $9.335 | $9.38 | 286.07K |
| Oct 15, 2026 | $9.42 | $9.7238 | $9.35 | $9.59 | 317.97K |
| Oct 14, 2026 | $9.24 | $9.295 | $9.15 | $9.25 | 292.2K |
| Oct 13, 2026 | $9.38 | $9.49 | $8.99 | $9.26 | 483.73K |
| Oct 12, 2026 | $9.15 | $9.30 | $9.12 | $9.28 | 336.22K |
| Oct 9, 2026 | $9.00 | $9.235 | $8.99 | $9.17 | 314.18K |
| Oct 8, 2026 | $9.18 | $9.30 | $8.855 | $9.00 | 588.1K |
| Oct 7, 2026 | $9.33 | $9.57 | $9.18 | $9.20 | 394.37K |
| Oct 6, 2026 | $9.53 | $9.59 | $9.38 | $9.41 | 392.83K |
| Oct 5, 2026 | $9.09 | $9.54 | $9.01 | $9.50 | 634.62K |
| Oct 2, 2026 | $9.26 | $9.33 | $9.07 | $9.09 | 319.19K |
| Oct 1, 2026 | $9.44 | $9.57 | $9.16 | $9.21 | 525.35K |
| Sep 30, 2026 | $9.75 | $9.75 | $9.38 | $9.41 | 588.03K |
| Sep 29, 2026 | $9.80 | $9.82 | $9.49 | $9.75 | 433.76K |
| Sep 28, 2026 | $9.33 | $9.865 | $9.19 | $9.84 | 438.1K |
The latest Smart Investors Daily articles mentioning OFIX.
Company
Market Activity
Research & News
OFIX research
Company profile and research snapshot.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Jul 6, 2026 | Barrington Research | Outperform | — |
| May 22, 2026 | Canaccord Genuity | Buy | — |
| May 22, 2026 | Stifel | Buy | — |
| May 22, 2026 | Barrington Research | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 12, 2026
The payments were made after a California arbitrator found private text messages between Orthofix executives couldn’t be considered cause for firing.
Benzinga · Aug 10, 2026
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $18 to $13.
ChartMill · Aug 5, 2026
Orthofix Medical (OFIX) beats Q2 profit estimates, raises full-year 2026 guidance; stock up ~9.6% premarket despite in-line revenue.
SeekingAlpha · Aug 5, 2026
Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call August 5, 2026 8:30 AM EDTCompany ParticipantsJulie Dewey - Chief Investor Relations & Communications...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning OFIX.